Table 1.
Cardiovascular therapies given to patients in the EAST-AFNET 4 trial at discharge from the baseline visit, at 12 months follow-up, and at 24 months follow-up
| Randomized group |
||||
|---|---|---|---|---|
| Early rhythm control (N = 1395) | Usual care (N = 1394) | Total (N = 2789) | P-value | |
| Patients receiving oral anticoagulation | ||||
| Anticoagulation (discharge from baseline) | 1267/1389 (91.2%) | 1250/1393 (89.7%) | 2517/2782 (90.5%) | 0.149 |
| NOACs (discharge from BL) | 800/1389 (57.6%) | 763/1393 (54.8%) | 1563/2782 (56.2%) | 0.103 |
| Vitamin K antagonists (discharge from BL) | 467/1389 (33.6%) | 490/1393 (35.2%) | 957/2782 (34.4%) | 0.397 |
| Anticoagulation (12 months FU) | 1087/1230 (88.4%) | 1121/1241 (90.3%) | 2208/2471 (89.4%) | 0.111 |
| NOACs (12 months FU) | 713/1230 (58.0%) | 704/1241 (56.7%) | 1417/2471 (57.3%) | 0.657 |
| Vitamin K antagonists (12 months FU) | 376/1230 (30.6%) | 421/1241 (33.9%) | 797/2471 (32.3%) | 0.100 |
| Anticoagulation (24 months FU) | 1020/1159 (88.0%) | 1065/1171 (90.9%) | 2085/2330 (89.5%) | 0.021 |
| NOACs (24 months FU) | 690/1159 (59.5%) | 699/1171 (59.7%) | 1389/2330 (59.6%) | 0.774 |
| Vitamin K antagonists (24 months FU) | 330/1159 (28.5%) | 366/1171 (31.3%) | 696/2330 (29.9%) | 0.202 |
| Patients receiving rate control therapy (beta adrenoreceptor blocker, verapamil, diltiazem, or digitalis glycosides) | ||||
| Rate control (discharge from BL) | 1088/1389 (78.3%) | 1235/1393 (88.7%) | 2323/2782 (83.5%) | <0.001 |
| Rate control (12 months FU) | 883/1230 (71.8%) | 1055/1241 (85.0%) | 1938/2471 (78.4%) | <0.001 |
| Rate control (24 months FU) | 799/1159 (68.9%) | 986/1171 (84.2%) | 1785/2330 (76.6%) | <0.001 |
| Patients receiving any rate controlling medication (beta adrenoreceptor blocker, verapamil, diltiazem, digitalis glycosides, or antiarrhythmic drugs with rate controlling propertiesa) | ||||
| Patients receiving any rate controlling medication (discharge from BL) | 1259/1389 (90.6%) | 1250/1393 (89.7%) | 2509/2782 (90.2%) | 0.382 |
| Patients receiving any rate controlling medication (12 months FU) | 1065/1230 (86.6%) | 1084/1241 (87.3%) | 2149/2471 (87.0%) | 0.588 |
| Patients receiving any rate controlling medication (24 months FU) | 968/1159 (83.5%) | 1013/1171 (86.5%) | 1981/2330 (85.0%) | 0.042 |
| Patients receiving diuretics | ||||
| Diuretics (discharge from BL) | 559/1389 (40.2%) | 561/1393 (40.3%) | 1120/2782 (40.3%) | 0.987 |
| Diuretics (12 months FU) | 508/1230 (41.3%) | 521/1241 (42.0%) | 1029/2471 (41.6%) | 0.788 |
| Diuretics (24 months FU) | 478/1159 (41.2%) | 507/1171 (43.3%) | 985/2330 (42.3%) | 0.299 |
| Patients receiving heart failure and antihypertensive therapy (ACE inhibitor, angiotensin receptor blocker, mineralocorticoid antagonists, and neprilysin/valsartan) | ||||
| Heart failure and antihypertensive therapies (discharge from BL) | 964/1389 (69.4%) | 988/1393 (70.9%) | 1952/2782 (70.2%) | 0.397 |
| Heart failure and antihypertensive therapies (12 months FU) | 854/1230 (69.4%) | 878/1241 (70.7%) | 1732/2471 (70.1%) | 0.482 |
| Heart failure and antihypertensive therapies (24 months FU) | 798/1159 (68.9%) | 837/1171 (71.5%) | 1635/2330 (70.2%) | 0.163 |
| Patients receiving diabetes therapy (oral antidiabetic medication and insulin) | ||||
| Antidiabetic therapy (discharge from BL) | 256/1389 (18.4%) | 254/1393 (18.2%) | 510/2782 (18.3%) | 0.873 |
| Antidiabetic therapy (12 months FU) | 238/1230 (19.3%) | 237/1241 (19.1%) | 475/2471 (19.2%) | 0.870 |
| Antidiabetic therapy (24 months FU) | 228/1159 (19.7%) | 227/1171 (19.4%) | 455/2330 (19.5%) | 0.924 |
| Patients receiving statins | ||||
| Statins (discharge from BL) | 628/1389 (45.2%) | 568/1393 (40.8%) | 1196/2782 (43.0%) | 0.016 |
| Statins (12 months FU) | 587/1230 (47.7%) | 526/1241 (42.4%) | 1113/2471 (45.0%) | 0.006 |
| Statins (24 months FU) | 576/1159 (49.7%) | 529/1171 (45.2%) | 1105/2330 (47.4%) | 0.020 |
All patient numbers are given split by randomized group and in total. Proportions indicate proportions of patients receiving each therapy at each time point as a fraction of the totality of patients still in follow-up and with available medication information at that time point. Anticoagulation, therapy with heart failure and antihypertensive drugs, antidiabetic therapy, and rate control therapy were used in most patients.
ACE inhibitor, angiotensin-converting enzyme inhibitor; BL, baseline visit; FU, follow-up; NOAC, novel oral anticoagulant.
Antiarrhythmic drugs with rate controlling properties are amiodarone, dronedarone, propafenone, and sotalol. P-values resulting from mixed logistic regression with centre as random effect.